Ulevostinag

Ulevostinag (MK-1454) is a synthetic cyclic dinucleotide and a potent small molecule agonist of the stimulator of interferon genes protein (STING). It was developed as an anti-tumor immunotherapy agent and acts by activating the STING pathway, which leads to the induction of type I interferons and other cytokines that promote anti-tumor immune responses. Ulevostinag has been investigated primarily for intratumoral administration in advanced or metastatic solid tumors, lymphomas, and head and neck squamous cell carcinoma. The drug was originally developed by Merck & Co/Merck Sharp & Dohme[1][3][4][5].

Other names

Cyclo((p3'r,2's)-2'-deoxy-2'-fluoro-p-thioadenylyl-(3'->5')-(p2'r)-3'-deoxy-3'-fluoro-p-thioguanylyl-(2'->5'))Guanosine (p(r))-2'-deoxy-2'-fluoro-5'-o-((r)-hydroxymercaptophosphinyl)-p-thio-.beta.-d-arabino-adenylyl-(3'->5')-3'-deoxy-3'-fluoro-, cyclic nucleotide